Twenty-three patients with organ-confined, low-risk prostate cancer have been treated with MR-guided focused ultrasound in clinical trials, showing promising initial results.
The goal of the trials is to demonstrate the feasibility of using the ExAblate® MR-guided Focused Ultrasound (MRgFUS) system in endorectal prostate treatments and to assess the safety and preliminary effectiveness of the treatment. The trials were approved by local ethic committees.
Clinical trials are ongoing at four sites: Sapienza University of Rome, Italy; The National Cancer Centre Singapore; The NN Petrov Institute of Oncology, St. Petersburg, Russia; and the Jaslok Hospital and Research Center, Mumbai, India. InSightec will soon be expanding the prostate clinical trials to additional locations.